Drug Profile
Nonacog beta pegol - Novo Nordisk
Alternative Names: 40K PEG-rFIX; Glycopegylated rFIX - Novo Nordisk; La-rFIX derivative - Novo Nordisk; N9 GP; NN 7999; NNC-0156-0000-0009; REBINYN; Rebinyn; RefixiaLatest Information Update: 19 Jan 2024
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class Antihaemorrhagics; Blood coagulation factors; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Blood coagulation factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Haemophilia B
Most Recent Events
- 17 Nov 2023 Novo Nordisk completes phase III paradigm™5 trial for Haemophilia B (in children) in USA, Canada, Brazil, United Kingdom, Italy, Croatia, France, Germany, Japan, Malaysia, Taiwan (IV) (NCT01467427) (EudraCT2011-000826-31)
- 21 Feb 2023 Registered for Haemophilia B (Prevention) in USA (IV)
- 27 Oct 2022 Novo Nordisk completes the phase III paradigm™6 trial for Haemophilia B (Prevention, In neonates, In infants, In children) in USA, Algeria, Argentina, Australia, Austria, Canada, France, Germany, Israel, Italy, Japan, Malaysia, Romania, Spain, Netherlands, Taiwan, Thailand, United Kingdom (IV) (NCT02141074) (EudraCT2012-004867-38)